Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers



Status:Recruiting
Conditions:Prostate Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Kidney Cancer, Bladder Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/22/2018
Start Date:October 19, 2017
End Date:November 2019
Contact:Julia Rasmussen, MS, RN, BSN
Email:julia.rasmussen@duke.edu
Phone:919-681-1030

Use our guide to learn which trials are right for you!

The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor
cells (HSPCs) to reconstitute a match human immune system in our PDX model. The hypothesis is
that by using matched leukocytes and PDX from the same patient, rejection of the PDX by the
host immune system will not be observed and therefore a preclinical model to study
immunotherapy can be developed to study, understand and improve upon our current therapies.
HSPCs will be collected from bone marrow aspirate obtained from a bone marrow biopsy.


Inclusion Criteria:

1. Patients with Genitourinary (GU) Cancers and presence of existing patient derived
xenograft or planned collection of tumor for PDX generation

2. Age ≥ 18 years.

3. Ability to understand and provide signed informed consent that fulfills Institutional
Review Board guidelines.

4. Ability to undergo bone marrow biopsy

5. Laboratory requirements (Hematocrit 30%, Platelets 75,000 + 10^6/l and WBC 4000 X
10^6/l)

Exclusion Criteria:

1. Participants with serious concurrent chronic or acute illness that would affect the
safety of a bone marrow biopsy.
We found this trial at
1
site
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Phone: 919-681-1030
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials